UK – Novavax COVID-19 vaccine found to be 89.3% effective in UK trial

A COVID-19 vaccine developed by Novavax, known as NVX-CoV2373, has demonstrated efficacy of 89.3% in a Phase III clinical trial conducted in the UK.

This study assessed the efficacy of the vaccine during the period in which the new UK virus strain was emerging and circulating widely.

It enrolled over 15,000 participants aged between 18-84 years, with 27% of that participants being over the age of 65.

The first interim analysis – based on 62 cases – found 56 cases of COVID-19 in the placebo group compared to six cases in the NVX-CoV2373 group.

This reflected a point estimate vaccine efficacy of 89.3%, with the preliminary analysis indicating that the UK variant was detected in over 50% of the PCR-confirmed symptomatic cases…